WATERS CORP
WATNYSETrading Snapshot
- Day Range
- $440.29 β $447.18
- 52-Week Range
- $282.77 β $436.34
- Volume
- $5.68B
- Avg Volume
- $6.25B
- Shares Outstanding
- 98.2M
- Next Earnings
- Dec 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.17B
- Last Q Revenue
- $1.65B
- P/E Ratio
- 107.8
- P/S Ratio
- 9.2x
- EPS (TTM)
- $1.69
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.2%
Why Investors Own WAT
- βHigh-growth profile β revenue up +21.1% YoY with expanding US Equity exposure.
- βHealthy economics β 39% gross margin and 8% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
WATERS CORP
WATAbout WATERS CORP
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
Waters NYSE: WAT President and Chief Executive Officer Udit Batra said the company's second-quarter performance exceeded expectations, supported by broad-based growth in its legacy analytical-science operations and early

Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript
Waters Corporation (WAT) Presents at U.S. All Stars Conference Transcript

Still Waters Bring Mixed Pre-Market Levels
A grand total of zero monthly or quarterly economic reports have come out so far this week.

Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT launches the BD FACSDiscover A7 globally, bringing advanced spectral flow cytometry, automation and standardized workflows to research labs.

Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
AUSTIN, Texas--(BUSINESS WIRE)--Everlywell, a leader in digital health, today announced a partnership with Waters Corporation to ensure patients have access to the most comprehensive at-home HPV cervical cancer screening

Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
Enables routine 50+ parameter experiments with BD SpectralFXβ’ Technology, accelerating breakthrough discoveries in the fight against cancer and other diseases. Minimizes instrument and user differences with first-of-its-